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Gene therapyII (MPSII) is an inherited disorder due to a deﬁciency of the lysosomal enzyme
iduronate-2-sulfatase (IDS). The disease is characterized by a considerable deposition of heparan- and
dermatan-sulfate, causing a general impairment of physiological functions. Most of the therapeutic protocols
proposed so far are mainly based upon enzyme replacement therapy which is very expensive. There is a
requirement for an alternative approach, and to this aim, we evaluated the feasibility of muscle electro gene
transfer (EGT) performed in the IDS-knockout (IDS-ko) mouse model. EGT is a highly efﬁcient method of
delivering exogenous molecules into different tissues. More recently, pre-treatment with bovine
hyaluronidase has shown to further improve transfection efﬁciency of muscle EGT. We here show that, by
applying such procedure, IDS was very efﬁciently produced inside the muscle. However, no induced IDS
activity was measured in the IDS-ko mice plasma, in contrast to matched healthy controls. In the same
samples, an anticipated and rapidly increasing immune response against the recombinant protein was
observed in the IDS-ko vs control mice, although reaching the same levels at 5 weeks post-injection.
Additional experiments performed on healthy mice showed a signiﬁcant contribution of hyaluronidase pre-
treatment in increasing the immune response.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionMucopolysaccharidosis type II (MPS II), Hunter syndrome, [MIM
309900] is a rare, X-linked lysosomal storage disorder (LSD) due to
the deﬁciency of the enzyme iduronate-2-sulfatase (IDS, EC
3.1.6.13) involved in the lysosomal catabolism of heparan- and
dermatan-sulfate. Two major forms of the disease, severe and
attenuated, are now recognized as having different progression and
life expectancy. The pathology is mainly characterized by the
accumulation of undegraded glycosaminoglycans (GAG) in spleen,
liver, heart, kidney, bone and joints, and in the most severe forms
it also involves the central nervous system leading to progressive
neurodegeneration.
Only palliative procedures and symptomatic therapies are cur-
rently available to treat this disorder. Haematopoietic stem cell
transplantation which has been successful for some other forms of
MPS [1–3], is ineffective in Hunter disease [4]. After the recent
conclusion of the phase III clinical trial [5], enzyme replacement
therapy (ERT) has become the elective therapy, although it is39 049 8213502.
).
rk.
ll rights reserved.expensive and, in addition, details of long term efﬁcacy are not yet
available.
Alternative therapeutic strategies have been evaluated including
gene transfer, mainly using viral vectors [6–11], together with a
somatic cell therapy approach [12].
Electro gene transfer (EGT) is a highly efﬁcient method of
delivering exogenous molecules into cells. It has been used to
introduce DNA into various mouse and rat tissues [13–18] and it
has also been successfully proposed to improve transfection of
skeletal muscle with plasmid DNA [16,19–25]. In fact, although
muscle represents a very accessible tissue, and therefore a good
gene transfer target, many drawbacks in obtaining high transfec-
tion efﬁciencies had been previously described by using direct
injection [26,27]. Attempts to further improve EGT efﬁciency have
included pre-treatment of the muscle with hyaluronidase (HYA)
[28–30].
In this paper we present our results on muscle electro gene
transfer applied to the MPS II mouse model [31] and to control mice.
The aimwas to evaluate the feasibility and efﬁciency of this procedure
when applied to the production and release of a systemic therapeutic
protein, iduronate-2-sulfatase. The use of the Hunter disease-mouse
model, characterized by null IDS activity in all the organ systems,
allowed a clearer evaluation.
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2.1. Plasmid construction
All cloning procedures were performed following standard
techniques [32]. Human IDS cDNA (kindly provided by J Hopwood,
Children, Youth andWomen's Health Service, Adelaide, Australia) had
been previously modiﬁed by Bielicki et al. in 1993 [33] by adding the
45 bp of the rat pre-proinsulin leader sequence. The cDNA had been
cloned by us in pvIJnsB [34] as previously described [22]. The resulting
plasmid, called pvIJIDS, carries the IDS cDNA sequence under CMV
trascriptional control and bovine growth hormone polyA.
2.2. Mice
C57BL6 control mice were purchased from Charles River Italia
while IDS-knockout (IDS-ko) mice were obtained from heterozygous
founders kindly provided by J. Muenzer (Chapel Hill, NC, USA).
The IDS-ko mouse model was created by replacing exon 4 and part
of exon 5 of the IDS gene with the neomycin resistance gene [35]. As
previously reported [12], knockout mice show no detectable plasma
and tissue IDS activity.
In the ﬁrst experiment a total of 9 IDS-ko and 12 healthymicewere
treated with EGT after pre-treatment with bovine hyaluronidase. All
animals were injected with 50 μg of plasmid DNA and seven further
healthy mice were injected with PBS only, as controls. Animals treated
at 12–16 weeks of age were euthanized at 3 time-points 1, 2, and
5 weeks post-injection and blood and tissue samples were collected
and analyzed.
In a second study, a total of 44 healthy mice were treated with the
same procedure. Only half of the mice were pre-treated with
hyaluronidase and animals were progressively euthanized 1, 2, 5 and
8 weeks later. Moreover, 18 mice not pre-treated with hyaluronidase
were injected with 1 μg of plasmid DNA and monitored for 5 weeks
post-treatment. Blood and tissue samples were collected and analyzed.
All animal experimentation was performed in accordance to
National and International Animal Ethic Guidelines.
2.3. Electro gene transfer (EGT)
EGT was performed on anaesthesized mice by injecting 50 μg of
plasmid DNA per animal diluted in 50 μl total saline into the quadricep
muscles. The mouse muscle was surgically exposed, injected and then
immediately electro-stimulated by inserting needle steel electrodes
around the injection site. The electric ﬁeld was applied in a pulsed
form by using a Pulsar 6 bp-a/s bipolar stimulator and pulses were
monitored with a digital oscilloscope. Mice were electrically stimu-
lated with ten trains of 1000 square bipolar pulses, maintaining
current control at 75 mA, delivered every other second, for a total
duration of 20.1 s. The frequency was 1000 Hz. Type VI-S hyalur-
onidase from bovine testis (36 units per animal), resuspended in 50 μl
sterile saline, was injected into the muscle 45 min before EGT, as
described by Mennuni and co-workers (2002).
2.4. IDS enzyme assay
IDS activity was evaluated by a ﬂuorimetric assay [36] requiring
the use of the substrate 4-methylumbelliferyl-α-iduronide-2-sul-
phate (Moscerdam Substrates, Erasmus University, Rotterdam, the
Netherlands). The assay was performed according to the manufac-
turer's instructions. Brieﬂy, 10 μg of protein per sample or 2 μl of
plasma were assayed by adding 20 μl of 1.25 mM substrate and
incubating at 37 °C for 4 h. Afterwards, 40 μl of double concentrated
McIlvains phosphate/citrate buffer and 10 μl of LEBT (Lysosomal
Enzymes puriﬁed from Bovine Testis) were added to each sample and
incubated at 37 °C for further 24 h. The reaction was stopped byadding 1420 μl per sample of stop buffer (0.5 M NaHCO3/0.5 M Na2CO3
pH 10.7, 0.025% Triton X-100); 4-methylumbelliferone (Sigma-Aldrich,
Milano, Italy) was used as standard. Fluorescence was measured at
355/460 nm excitation/emission in a Victor 2 1420 Multilabel Counter
Fluorometer (Wallac-Perkin Elmer). Enzyme activity was given as
nmoles of substrate hydrolysed in 4 h per mg of total protein or per ml
of plasma [nmol/4 h/mg or nmol/4 h/ml]. Tissue samples were ﬁrst
homogenized in lysis buffer (10 mM Tris–HCl pH 7.4, 150 mM NaCl,
1 mM EDTA pH 8.0, 0.1% Triton X-100) and, following centrifugation,
the supernatants were recovered. All samples were evaluated for
protein content by using the BIORAD protocol. Plasma samples were
obtained from heparinized blood, microcentrifuged at 3000 rpm for
20 min.
2.5. Anti-iduronate-2-sulfatase antibodies determination
Anti-iduronate-2-sulfatase antibodies were measured by using an
immunoprecipitation assay [12]: 5 μl of mouse plasma was diluted in
40mMTris–HCl, pH 8.0 to a ﬁnal volume of 60 μl, mixedwith 80 nmol/
4 h of iduronate-2-sulfatase collected from over-expressing C2C12 cell
medium and incubated at 4 °C overnight. The day after, samples were
incubated with 20 μl of Pansorbin protein A (200 mg/ml) (Calbiochem,
INALCO, Milano, Italy) and centrifuged to pellet iduronate-2-sulfatase
bound to Pansorbin in the presence of anti-iduronate-2-sulfatase
antibodies. The unbound enzyme in the supernatant was measured
with the ﬂuorometric assay. Antibody titre was expressed as
percentage of IDS immunoprecipitated by the antibodies, with respect
to the initial IDS content. Negative control was obtained by incubation
of an equal amount of plasma from ko untreated mice. For the positive
control 80 nmol/4 h of IDSwere incubatedwith 9 μg total of a goat anti-
human IDS polyclonal antibody (kindly provided by Shire-TKT, Cam-
bridge, MA, USA) in order to completely abolish the enzyme activity.
2.6. Tissue glycosaminoglycan content
Tissue GAG content (expressed as μg of GAG/mg of protein) was
measured as previously suggested [37]. Before performing the assay,
tissues were lyophilised, resuspended and homogenized in 0.9%
NaCl+0.2% Triton X-100. Samples were then shaken overnight at
4 °C and microcentrifuged for 5′ at 3000 rpm. Supernatants were
collected and kept at −80 °C until analysis. 50 μl of blank (water),
calibrators (chondroitin sulfate C, Sigma-Aldrich, Milano, Italy) and
samples in duplicate were incubated with 50 μl of 8 M Guanidine-
hydrochloride for 15 min at room temperature, with 50 μl of SAT
solution (0.3% sulfuric acid, 0.75% Triton X-100) for 15 min and with
a solution of Alcyan blue 0.038% overnight. Afterwards, samples
were centrifuged and rinsed with a DMSO washing solution (40%
DMSO, 0,05% Magnesium chloride). After centrifugation, pellets
were resuspended in Gu-Prop (4 M Guanidine-hydrocloride, 33%
Isopropanol, 0.25% Triton X-100) and absorbance was measured at
620 nm.
2.7. Statistical analysis
Data represent the average of different samples, the number of
which is indicated under each ﬁgure. Bars represent SEM (mean
standard error). Statistical comparisons of experimental groups were
performed using a Student's t-test. p values less than 0.05 were
considered statistically signiﬁcant.
3. Results
3.1. Experimental plan
We ﬁrst evaluated the EGT procedure for the release of iduronate-
2-sulfatase in hyaluronidase pre-treated IDS-ko and control mice. In a
Fig. 2. IDS activity detected in healthy mice plasma before and after EGT treatment.
Blood samples were taken at sacriﬁce 1, 2 and 5 weeks post-injection and IDS activity is
given as nmol/4 h/ml of plasma. n=10 for basal level (0); n=4, 3, 5 at 1, 2, 5 weeks.
⁎=statistically signiﬁcant increase with respect to basal level, pb0.05.
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the efﬁcacy of the procedure in animals pre-treated and not pre-
treated with hyaluronidase.
3.2. EGT in hyaluronidase pre-treated IDS-ko mice
3.2.1. IDS activity induced in quadricep muscles
Our ﬁrst evaluation was performed in a total of 9 IDS-ko and 12
healthy mice treated with EGT (after injection of 50 μg of the
plasmid DNA pvIJIDS per animal) and pre-treated with bovine HYA.
Nine further healthy animals underwent EGT following injection of
PBS only, and were used as controls. Mice were euthanized at 3
time-points: 1, 2 and 5 weeks post-injection. Quadriceps were
removed, homogenized and evaluated for IDS activity by perform-
ing a ﬂuorometric assay, and the results are shown in Fig. 1. The
basal enzyme level reported (9.8±1.9 nmol/4 h/mg) was calculated
in quadricep muscles from PBS injected healthy animals (indicated
as UT wt), while no basal IDS activity was measured in the IDS-ko
mice (data not shown). The difference between electro-injected
muscles and the basal level was assumed to represent enzyme
activity due to the recombinant protein. In all groups, a
signiﬁcantly increased activity (pb0.0001) of at least six fold
(63.8±10.8 nmol/4 h/mg) with respect to the basal value (9.8±
1.9 nmol/4 h/mg) was detected, reaching a level 24-fold higher
(234.9±46.5 nmol/4 h/mg) than baseline in healthy mice eutha-
nized 5 weeks post-treatment.
3.2.2. IDS activity measured in plasma
In the same animals we evaluated plasma IDS activity (Fig. 2). Since
our previous experience showed that IDS plasma level in adult mice
maintains constant with time (data not shown), we took as comparing
level for the present experiment the mean activity detected before
treatment (basal level, time 0, 74.8±14.8 nmol/4 h/ml). A higher IDS
activity with respect to the control value was detected in the healthy
mice 2 and 5 weeks post-treatment, with a maximum increment of
about 30 units (+34%) (100.4±32.1 nmol/4 h/ml, pb0.05) at 5 weeks;
in contrast no induced activity was measured in the IDS-ko animals
(not shown in the ﬁgure).Fig. 1. IDS activity detected in healthy and IDS-ko mice quadricep muscles before and
after EGT treatment. Animals were euthanized 1, 2 and 5 weeks post-injection and IDS
activity is given as nmol/4 h/mg of protein. UT wt=PBS injected healthy mice (n=9); T
wt=treated healthy mice euthanized at 1, 2, 5 weeks (n=4, 3, 5 respectively); T IDS ko =
IDS-ko mice euthanized at 1, 2, 5 weeks (n=3 at all time-points). Muscle IDS activity in
UT IDS-ko mice, being undetectable, is not reported in the ﬁgure. ⁎⁎⁎ = statistically
signiﬁcant increase with respect to basal level, p≤0.0001.3.2.3. Anti-IDS immune response
The amount of speciﬁc anti-IDS antibodies raised by the treatment
was evaluated in the animal's plasma. The analysis was performed in
both ko and wt mice at different time-points, by using an
immunoprecipitation assay. Starting from a known IDS activity, we
evaluated the residual activity following immunoprecipitation with
the plasma of the treated animals. Results, given as percentage (%) of
IDS activity neutralized by the plasma antibodies, are reported in Fig. 3
and show an increasing amount of neutralizing antibodies from 1 to
5 weeks post-treatment. In particular, a considerably higher immune
response was detected in IDS-ko mice with respect to controls at
2 weeks (53% vs 11% of IDS immunoprecipitated, pb0.001).
3.2.4. Tissue IDS activity and gag content
IDS activity was also measured in liver, spleen, kidney, lung, heart
and contralateral quadricep muscle of the treated IDS-ko mice.
Enzyme activity detected was around 0 nmol/4 h/mg of protein
(data not shown). In the same organs glycosaminoglycan content
measured 5 weeks post-treatment did not decrease with respect to
untreated tissues (data not shown).
3.3. EGT in hyaluronidase pre-treated and not pre-treated control mice
3.3.1. IDS activity induced in quadricep muscles
In a second experiment forty-four wild type animals were treated
with the same procedure, half of which were pre-treated with HYAFig. 3. Immune response induced by the treatment in healthy and IDS-ko mice plasma,
measured as % of IDS immunoprecipitated by anti-IDS antibodies. n=4, 3, 5 for healthy
mice euthanized (T wt) at 1, 2, 5 weeks; n=3 for IDS-ko mice (T IDS ko) euthanized at all
time-points. ⁎=statistically signiﬁcant increase with respect to healthy mice, pb0.001.
Fig. 5. IDS activity detected in healthy mice plasma before and after EGT treatment
performed with or without hyaluronidase. Blood samples were taken once aweek, from
0 to 8 weeks post-injection and IDS activity is given as nmol/4 h/ml of plasma. For basal
level (0) n=44. W/O HYA=animals in which EGT was performed without pre-treatment
with hyaluronidase, n=4–22 at different time-points; W HYA = animals in which EGT
was performed with hyaluronidase pre-treatment, n=5–22 at different time-points. ⁎ =
statistically signiﬁcant increase with respect to basal level, p≤0.05; ⁎⁎⁎ = statistically
signiﬁcant increase with respect to basal level, p≥0.0001; #=statistically signiﬁcant
increase of W/O HYA samples vs W HYA samples, p≤0.05.
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2, 5 and 8weeks later. Fig. 4 shows the enzyme activity detected in the
mice quadriceps obtained post-euthanasia. As in the previous
experiment, the difference between electro-injected muscles and
the basal level was assumed to represent enzyme activity due to the
recombinant protein. In most animals enzyme activity appeared
signiﬁcantly higher than baseline (9.8±1.9 nmol/4 h/mg, indicated as
UT in the ﬁgure). Moreover, it was signiﬁcantly higher in HYA pre-
treated versus not pre-treated animals (pb0.0001), reaching a 20 fold
increase (187.5±32.4 nmol/4 h/mg), with respect to basal level at
8 weeks.
3.3.2. IDS activity measured in plasma
Fig. 5 reports plasma IDS levels measured in the EGT-treated
animals. Mice were monitored weekly by retro-orbital bleeding. T0
represents pre-treatment values. A sudden increase of the activity
was measured 1 week post-injection in both groups of samples
(around +40%, pb0.0001). In the following time-points, up to
5 weeks, variable levels of activity were detected, some of which
signiﬁcantly increased compared to baseline, as indicated in the
ﬁgure. The activities measured were quite similar between the two
groups of animals. At 6, 7 and 8 weeks post-treatment samples
collected from mice which were not treated with HYA showed a
higher level of enzyme activity with respect to the group of mice pre-
treated (+39%, +24.5%, +29% respectively). In particular, such
increase was statistically signiﬁcant 6 and 7 weeks post-treatment
(pb0.01).
3.3.3. Anti-IDS immune response
The appearance of speciﬁc anti-IDS antibodies was monitored
weekly in the plasma of both animal groups (Fig. 6). Neutralizing
antibodies were measurable starting 2 weeks post-treatment and
progressively increasing for the entire follow-up. The amount of
antibodies detected in the samples derived frommice that underwent
HYA pre-treatment was higher than that detected in the plasma
obtained from animals that were not pre-treated with HYA, in the ﬁrst
group up to 50% of the IDS activity was immunoprecipitated by the
antibodies. There was up to a four fold difference between the two
groups at weeks 5 and 8 post-injection. Statistical analysis showed
signiﬁcant differences between the 3rd and 7th week of treatment
(pb0.005 at weeks 3 and 4, pb0.0001 at weeks 5, 6, 7).Fig. 4. IDS activity detected in mice quadricep muscles before and after EGT treatment
performed with or without hyaluronidase. Animals were euthanized 1, 2, 5 and 8 weeks
post-injection and IDS activity is given as nmol/4 h/mg of protein. UT = untreated
healthy mice, n=9; W/O HYA=animals in which EGT was performed without pre-
treatment with hyaluronidase, n=5, 6, 6, 5 for mice euthanized at 1, 2, 5, 8 weeks; W
HYA = animals in which EGT was performed with hyaluronidase pre-treatment, n=6, 5,
5, 6 for mice euthanized at 1, 2, 5, 8 weeks. ⁎ = statistically signiﬁcant increase with
respect to basal level, p≤0.05; ⁎⁎⁎ = statistically signiﬁcant increase with respect to
basal level, p≤0.0001; # = statistically signiﬁcant increase of W HYA samples vs W/O
HYA samples, p≤0.005.Finally, a further decrease of the immune responsewas observed in
a subsequent experiment, inwhichwe injected 18 animalswith 1 μg of
DNA. Results showed, 5 weeks post-treatment, a reduction from 10 to
5% of the IDS immunoprecipitated, compared to injection of 50 μg of
plasmid DNA without HYA pre-treatment. However, in this experi-
ment we did not register a signiﬁcant increase of plasma IDS activity
with respect to basal level.
3.3.4. IDS activity measured in tissues
IDS activity was also measured in liver, spleen and contralateral
quadricep muscles of the treated healthy mice. Data shown in Table 1
present the comparison between the two groups of animals
euthanized at 5 and 8 weeks post-injection. An increased enzyme
activity was seen in the spleen of mice not pre-treated with
hyaluronidase at 5 and 8 weeks post-treatment, in the spleen of
HYA pre-treated animals at 5 weeks and in the liver of not-pre-treatedFig. 6. Immune response induced in mice plasma by EGT, performed with or without
hyaluronidase, measured as % of IDS immunoprecipitated by anti-IDS antibodies. W/O
HYA = animals inwhich EGT was performedwithout pre-treatment with hyaluronidase,
n=4–22 at different time-points; W HYA = animals in which EGT was performed with
hyaluronidase pre-treatment, n=5–22 at different time-points. ⁎⁎ = statistically
signiﬁcant increase of W HYA samples vsW/O HYA samples, p≤0.005; ⁎⁎⁎ = statistically
signiﬁcant increase of W HYA samples vs W/O HYA samples, p≤0.0001.
Table 1
IDS activity detected in mice tissues: comparison between hyaluronidase pre-treated
and not pre-treated animals
Basal levela 5 wb 8 wb
Liver 16.5±0.6 −HYA 22.7±4.9 17.6±2.2
+HYA 17.9±1.3 16.9±0.8
Spleen 21.1±1.7 −HYA 25.3±1.8 25.5±1.9
+HYA 26.8±3.3 21.8±1.5
Cl muscle 9.8±1.9 −HYA 10.8±3.7 7.3±2.7
+HYA 8.4±1.3 8.8±1.2
5 w and 8 w=weeks post-treatment, HYA=hyaluronidase, Cl: contralateral muscle.
IDS activity is given as nmol/4 h/mg of protein.
a Tissue IDS activity in not treated healthy mice.
b Tissue IDS activity in treated healthy mice.
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signiﬁcant with respect to basal level.
4. Discussion
EGT is a common procedure for efﬁcient targeted transduction of
genes of interest. It has been applied to numerous tissues and organs
in several animal models [13–18] and, in particular, it has been
proposed to improve transfection of skeletal muscle with plasmid
DNA [16,19–25]. EGT has signiﬁcantly improved muscle gene
transduction, allowing a several fold increase in the amount of
recombinant protein produced. Moreover, the procedure has been
more recently optimized by pre-treatment of the muscle with
hyaluronidase [28,29], which has further increased its performance.
We here evaluated the feasibility of utilizing muscle EGT for the
efﬁcient production and release of iduronate-2-sulfatase in the IDS-ko
mousemodel. IDS is a lysosomal enzyme involved in the catabolism of
the glycosaminoglycans heparan and dermatan-sulfate. A deﬁciency
in this enzyme activity is responsible for a genetic disease called
Hunter syndrome or mucopolysaccharidosis type II (MPS II). The
intravenous infusion of the recombinant enzyme has shown to
improve the pathological phenotype; however, it remains extremely
expensive (around 300,000 Euros/patient/year) and the search for
new therapies is thus of primary importance.
It has recently been suggested that very small amounts of a
lysosomal protein (3–5% of normal) would be sufﬁcient for the
effective treatment of a speciﬁc LSD [38,39]. These data strongly
encourages a gene therapy approach, albeit the amount of recombi-
nant protein produced, released and taken up by the different tissues
is very difﬁcult to control.
Muscle EGT has never been assayed so far in animal models as a
potential tool for gene therapy of lysosomal disorders. Previous works
proposing muscle transduction for the treatment of these pathologies,
had been performed using viral vectors, either adenovirus or adeno-
associated virus, obtaining contradictory results. Enzyme release,
uptake by the peripheral organs and a therapeutic effect were
observed for Pompe [40] and Fabry diseases [41], while no release
from the muscle was described for MPS VII [42] and MPS VI [43].
We here reported the experiments performed in the IDS-ko and
wild type animal muscles, both pre-treated with hyaluronidase, to
evaluate the efﬁcacy of the procedure for IDS muscle production and
its release into the plasma. The results showed an elevated production
of the protein inside the muscle, but a limited release into the
bloodstream and a strong anti-IDS immune response, which likely
cleared the plasmatic fraction of the recombinant protein. To elucidate
this sudden and strong immune reaction we performed an additional
experiment on healthy control mice, half of which were pre-treated
with hyaluronidase and half were not.
In the ﬁrst experiment healthy and IDS-ko mice showed a very
high induced enzyme activity in the muscle, up to 24 fold and 14 fold
higher respectively than baseline wild type level. Since the pathologypresents a systemic involvement, to obtain therapeutic efﬁcacy the
recombinant protein needs to escape the muscle, enter the blood
stream and reach the organs. Our experiments suggest that a small
part of the large amount of IDS produced was released by the
quadriceps since an increased IDS activity with respect to baseline
level was detected in the plasma of the control animals. However, such
activity showed values hardly detectable in the knock out mice
plasma, where conversely an anticipated and stronger immune
response with respect to the healthy animals was detected. This
immune reaction started 2weeks post-treatment and reached levels 5
fold higher than that measured in the control mice. In the latter an
important immune response was detected at 5 weeks post-treatment.
As a consequence, no induced activity was found in the organs
analyzed from ko mice: liver, spleen, kidney, lung, heart and
contralateral muscle.
Could this immune reaction be due to the procedure in itself? It is,
in fact, well known that muscle per se is an important route of
immunization: might hyaluronidase represent an adjuvant in such an
immune reaction?
To address these questions we performed a second set of injections
in healthy control mice, either pre-treated or not pre-treated with
hyaluronidase. For this analysis we treated healthy animals because
the reduced and slower anti-IDS antibodies production expected in
these animals versus IDS-ko mice would have allowed a clearer
evaluation of the immunogenicity of the procedure per se.
Comparison of the results obtained in the control animals pre-
treated with hyaluronidase in the two experiments performed,
showed a very good reproducibility of the procedure although carried
on at two different times in two different batches of mice.
As previous papers had already shown [28,29], hyaluronidase pre-
treatment of the muscle signiﬁcantly improves the outcome of EGT,
with notable increases in the amount of protein produced inside the
muscle. In our experiment, we observed an IDS level enhanced up to
six fold in HYA pre-treated muscle versus not pre-treated. However,
the present data suggest that the amount of recombinant protein
released in the blood stream represents only a small amount of the IDS
produced by the treated muscle, and we did not detect any signiﬁcant
differences between hyaluronidase pre-treated and not pre-treated
animals up to 5 weeks post-injection. Starting at 6 weeks the IDS
activity measured in the plasma derived from HYA-treated animals
went back to baseline level, whilst the activity measured in not pre-
treated mice remained at signiﬁcantly higher levels with respect to
baseline, until the end of the follow-up. This was shown to be related
to the immune response against IDS: in pre-treated animals we
detected a quicker and stronger immune reaction, which, starting at
5 weeks post-treatment, consistently maintained about four fold
higher than that measured in the animals not pre-treated.
Previous experience by using recombinant IDS in preclinical
experiments [12,44] did not support for the protein an important
immunogenic role in the short period. Therefore, present results
suggest that most of the immune response here observed might have
been caused by the administration route in itself, and that hyalur-
onidase might act as an adjuvant. In any case, analysis of the organs
(liver, spleen, contralateral muscle) obtained from the euthanized
animals at different time-points post-treatment, did not detect
signiﬁcant increases of IDS activity with respect to baseline levels,
nor showed any differences between the two groups of animals.
Our data suggest that the muscle is a closed system in which only
small amounts of the recombinant IDS produced can escape and reach
the blood stream, and this seems to be independent from the amount
of protein produced. This would seem to be different from what
happens to proteins speciﬁcally directed or targeted to the blood
stream, such as erythropoietin, interferon, interleukins and VEGF
[25,45–47] for which a good release had been described.
As for lysosomal enzymes in general, the results published so far
seem to be quite disappointing and contradictory. The transgene was
579A. Friso et al. / Biochimica et Biophysica Acta 1782 (2008) 574–580always delivered to the muscle by a viral vector, and only few authors
demonstrate a release of the enzyme into the blood stream [39,41].
Other authors rather suggest that the enzyme activity observed
outside of the target muscle might be due to a spill over of the virus at
the time of injection [42,43].
In conclusion, we here conﬁrmed that muscle electro gene transfer
can very efﬁciently produce recombinant proteins inside the target
muscle, in this case the iduronate-2-sulfatase; hyaluronidase pre-
treatment signiﬁcantly improved the outcome of the procedure.
However, we could not detect a high release of the protein from the
producing muscle, either HYA pre-treated or not. Instead we observed
an important anti-IDS immune reaction, which was increased by HYA
pre-treatment.
Although EGT might be proposed as a tool to efﬁciently produce
proteins used by the muscle, such as dystrophin for the treatment of
muscular dystrophy, or for the efﬁcient release of proteins speciﬁcally
targeted to the circulation, such as erythropoietin or factor VIII or IX
for the treatment of blood disorders, our study shows that EGT
performed in the described conditions cannot successfully determine
an efﬁcient release of iduronate-2-sulfatase from the injected muscle,
necessary for the treatment of Hunter disease.
The application of this procedure to pathologies caused by
housekeeping genes, which involve most of the organ systems,
whose treatment thus requires a body-wide distribution of the
protein is an area in need of improvement, which might take
advantage by technical modiﬁcations such as the use of external
plate electrodes and/or the high voltage-low voltage combination,
providing a more homogenous distribution of the electric ﬁeld and a
reduction of the tissue damage.
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